WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Resources > Whitepapers > Manual No More: Automating the Scientific Data Lifecycle
May 23, 2022
I'm For Real
Enter your details once to access all our information and resources
Our Mission is to serve patients who have significant unmet medical needs and are underserved. To solve challenges for therapeutic developers and .
whitePaper | September 15, 2022
The sheer size of the pharmaceutical industry makes it important for all stakeholders to stay up to date with pharmaceutical industry trends.
whitePaper | January 1, 2020
Life sciences is facing a number of disruptors: novel cell and gene therapies that will revolutionize manufacturing, drug delivery and pricing models; a battle for the best and brightest talent; political and public pressure on the price of medication as well as the implications of the fourth industrial revolution. These factors combine to make investment decisions more challenging. With life sciences firms placing an increasing focus on the most efficient use of capital and shorter delivery times, project delivery providers are striving to come up with leaner and more innovative strategies and solutions to meet these needs. Integrated Project Delivery (IPD) is one such strategy.
whitePaper | December 22, 2022
According to research, post-pandemic R&D growth is healthy in the pharma industry with the number of drugs in the R&D pipeline now exceeding 20,000 in 2022—which represents an expansion rate of 8.22% from 2021 (1).
whitePaper | April 26, 2022
The prevalence of communicable and non-communicable diseases are increasing worldwide, placing considerable demand on public health systems and driving a necessity to develop more effective targeted therapies.
whitePaper | March 23, 2023
Sweden is and should remain a leading life sciences nation. The life sciences industry is one of Sweden’s economic base industries with a signifi cant share of our exports.
whitePaper | March 16, 2020
With the rapid onset of coronavirus in the United States, many pharma companies are being forced to prepare for a scenario in which their reps cannot visit providers and patients are limited in their ability to visit their healthcare professionals (HCP). The CDC has gone as far as recommending the use of telemedicine and patient portals as primary channels for HCPs and patients to interact.
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE